Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

ed to the market launch of a product containing a flavor ingredient from our Bitter Blocker program.

Costs of commercial revenues were $303,000 for 2012 compared to $219,000 for 2011.  Costs of commercial revenues were $100,000 for the fourth quarter of 2012 compared to $66,000 for the fourth quarter of 2011.  These increases are consistent with the corresponding increases in commercial revenues.  These amounts are comprised entirely of royalty payments related to certain in-licensed technologies.Research and development expenses, including stock-based compensation expense, were relatively flat at $28.6 million for 2012 compared to $28.7 million for 2011.  Research and development expenses, including stock-based compensation expense, were $7.2 million for the fourth quarter of 2012 compared to $7.1 million for the fourth quarter of 2011.

General and administrative expenses, including stock-based compensation expense, were relatively flat at $11.6 million for 2012 compared to $11.5 million for 2011.  General and administrative expenses, including stock-based compensation expense, were $3.1 million for the fourth quarter of 2012 compared to $3.2 million for the fourth quarter of 2011.

The net loss for 2012 was $0.23 per share, compared to $0.22 per share for 2011.  The net loss for the fourth quarter of 2012 was $0.06 per share compared to a net loss of $0.04 per share for the fourth quarter of 2011.

Financial Outlook:"Senomyx ended 2012 with a healthy balance sheet, including nearly $42 million in cash and no debt.  For the full year 2012, the Company delivered results in-line with financial guidance," stated Tony Rogers, Senior Vice President and Chief Financial Officer.

For the full year 2013, Senomyx expects:

  • Total revenues of $31 million to $34 million
  • Total operating expenses of $41 million to $43 million, of which approximately $4 million is non-cash, st
    '/>"/>

  • SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    7. WuXi PharmaTech Announces Third-Quarter 2011 Results
    8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    9. Spherix Announces Third Quarter Financial Results
    10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... ... , ... Costello served as Lead Levee Design Engineering Manager for a feasibility ... area from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... for providing protection, Costello also balanced socio-economic and environmental needs and concerns. ...
    (Date:7/28/2015)... 29, 2015 A ... rapidly developing and commercialising innovative medicines to transform ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality ... c. £76.5m), gross, from blue chip institutional investors and ...
    (Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
    (Date:7/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) has ... and Freezers Market - Global Industry Analysis, Size, ... report to their offering. ... been segmented based on applications: hospitals, research laboratories, ... others segment includes applications of biomedical refrigerators and ...
    Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3
    ... Vaccinogen, Inc. announced that,its new vaccine to ... in Europe starting June 2008., "This makes ... cancer," said Dr. Michael G. Hanna, Jr., Ph.D., ... of our worldwide strategy of profitable,distribution. Questions of ...
    ... ROCK, Ark., Feb. 27 Cauley Bowman Carney ... acquisition of,CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI ). ... entered into a definitive merger agreement,with an affiliate ... the proposal,CollaGenex,s shareholders would receive $16.60 per share ...
    ... COLLECTION, PROCESSING AND STORAGE OF EQUINE ... PLACENTAL TISSUE STEM CELLS, RANCHO CORDOVA, Calif., Feb. ... supplier of innovative products and,services that process and store ... Inc., has signed a formal agreement with,the UC Davis ...
    Cached Biology Technology:Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 3ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 4ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 5
    (Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
    (Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
    (Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
    Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
    ... North Hollywood, CA August 13, 2009 - The ... and support for myeloma patients, families, researchers and physicianstoday ... link between environmental toxins and bone disease in multiple ... of cells in the bone marrow that affect production ...
    ... the splendidly colorful leaves adorning the trees are a delight ... yellow, while the United States and East Asia boast lustrous ... differences in autumnal hues around the world? A new theory ... Education- Biology at the University of Haifa-Oranim and Prof. Jarmo ...
    ... deaths has declined steadily in the last three decades. ... age groups have shown some improvement, according to a ... of the American Association for Cancer Research. ... better treatment, have resulted in profound gains, but these ...
    Cached Biology News:New study suggests possible genetic links between environmental toxins and multiple myeloma 2Why are autumn leaves red in America and yellow in Europe? 2Why are autumn leaves red in America and yellow in Europe? 3Cancer mortality rates experience steady decline 2
    ... Kit is designed for fast and easy ... cells and tissues. The bead beating technology ... isolation procedures such as CTAB, phenol, or ... precipitation is not necessary - purified DNA ...
    The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
    ... The ApopTag Fluorescein Direct ... detects apoptotic cells in situ ... The DNA fragments are tagged ... nucleotide. The kit provides fluorescence ...
    ... APO-BRDU Kit is a two ... and total cellular DNA to detect apoptotic ... contains the instructions and reagents required for ... negative control cells for assessing reagent performance; ...
    Biology Products: